Siplizumab in T1DM

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

May 14, 2025

Study Completion Date

October 30, 2025

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Siplizumab

Weekly siplizumab doses for a total of 12 weeks

Trial Locations (12)

10032

Columbia University Medical Center: Naomi Berrie Diabetes Center, New York

30307

Emory University School of Medicine: Emory & Children's Pediatric Research Center, Division of Endocrinology & Diabetes, Atlanta

33136

University of Miami Miller School of Medicine: Diabetes Research Institute, Miami

35294

University of Alabama at Birmingham: Division of Endocrinology, Diabetes and Metabolism, Birmingham

52242

University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes, Iowa City

55454

University of Minnesota Medical School: Division of Pediatric Endocrinology and Diabetes, Minneapolis

64108

Children's Mercy Hospitals and Clinics: Section of Pediatric Endocrinology and Diabetes, Kansas City

75390

University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology, Dallas

80045

University of Colorado School of Medicine: Barbara Davis Center for Diabetes, Aurora

94143

UCSF School of Medicine: UCSF Diabetes Clinic, San Francisco

98101

Benaroya Research Institute at Virginia Mason: Diabetes Research Program, Seattle

02215

Joslin Diabetes Center: Joslin Clinic, Boston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH